Amalgamated Bank Sells 179 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Amalgamated Bank decreased its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 10.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,491 shares of the medical instruments supplier’s stock after selling 179 shares during the period. Amalgamated Bank’s holdings in Mesa Laboratories were worth $129,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of MLAB. Ranger Investment Management L.P. lifted its stake in shares of Mesa Laboratories by 1.2% in the fourth quarter. Ranger Investment Management L.P. now owns 226,682 shares of the medical instruments supplier’s stock worth $23,749,000 after buying an additional 2,689 shares in the last quarter. Boone Capital Management LLC purchased a new stake in Mesa Laboratories during the 4th quarter valued at $6,712,000. Los Angeles Capital Management LLC bought a new stake in shares of Mesa Laboratories in the 1st quarter worth $605,000. Allspring Global Investments Holdings LLC increased its holdings in shares of Mesa Laboratories by 66.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,044 shares of the medical instruments supplier’s stock worth $553,000 after purchasing an additional 2,010 shares in the last quarter. Finally, Conestoga Capital Advisors LLC raised its stake in shares of Mesa Laboratories by 0.4% in the first quarter. Conestoga Capital Advisors LLC now owns 580,744 shares of the medical instruments supplier’s stock worth $63,725,000 after purchasing an additional 2,281 shares during the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Mesa Laboratories Stock Up 0.4 %

Mesa Laboratories stock opened at $130.39 on Wednesday. The stock has a market cap of $705.28 million, a PE ratio of -2.77 and a beta of 0.85. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.37 and a current ratio of 1.94. The stock has a fifty day moving average of $123.11 and a 200 day moving average of $110.55. Mesa Laboratories, Inc. has a one year low of $82.86 and a one year high of $141.17.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings data on Monday, August 5th. The medical instruments supplier reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.74 by $0.55. Mesa Laboratories had a negative net margin of 111.89% and a positive return on equity of 18.95%. The company had revenue of $58.17 million for the quarter, compared to the consensus estimate of $55.90 million. As a group, sell-side analysts predict that Mesa Laboratories, Inc. will post 7.91 EPS for the current year.

Mesa Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Friday, August 30th were paid a $0.16 dividend. The ex-dividend date was Friday, August 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.49%. Mesa Laboratories’s dividend payout ratio (DPR) is -1.36%.

Analysts Set New Price Targets

MLAB has been the subject of a number of recent analyst reports. Wells Fargo & Company started coverage on Mesa Laboratories in a research report on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 target price for the company. Evercore ISI increased their price objective on shares of Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Tuesday.

Insider Buying and Selling

In other Mesa Laboratories news, SVP Brian David Archbold sold 1,499 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $125.00, for a total transaction of $187,375.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.20% of the stock is owned by insiders.

About Mesa Laboratories

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.